Eight years' experience with the Medtronic-Hall valve prosthesis.
During the period January 1981 to September 1986, 444 Medtronic-Hall heart valve prostheses were implanted in 351 patients (mean age, 45 +/- 10 years) mainly for rheumatic valve disease (63.2%). Most of the patients were in New York Heart Association functional class III. Concomitant surgical procedures, mainly conservative tricuspid or mitral procedures or coronary artery bypass grafting, were performed in 101 patients (28.7%). Single-valve replacement was performed in 262 patients (74.6%) (aortic in 117 patients, mitral in 143, and tricuspid in 2), double-valve replacement in 85 (24.2%) (mitral and aortic in 83 and mitral and tricuspid in 2), and triple-valve replacement in 4 (1.1%). Hospital mortality was 6.2%. Follow-up was 97.7% complete. The overall actuarial 8-year survival rate was 77.2%. The linearized incidence of valve-related complications was as follows: thromboembolism, 1.5%/patient-year; reoperation, 1.5%/patient-year; endocarditis, 1.25%/patient-year; hemolysis, 0.52%/patient-year; anticoagulant-related hemorrhage, 0.39%/patient-year; and noninfection-related paraprosthetic leak, 0.33%/patient-year. There were no instances of structural failure. We conclude that after 8 years of follow-up, the Medtronic-Hall valve prosthesis has an excellent clinical performance and a low range of valve-related complications.
Department of Cardiac Surgery, General Hospital Gregorio Marañon, School of Medicine, Universidad Complutense, Madrid, Spain.
J L
JL
Vallejo
J M
JM
Gonzalez-Santos
J
J
Albertos
M J
MJ
Riesgo
M E
ME
Bastida
M J
MJ
Rico
F
F
Gonzalez-Diego
R
R
Arcas
D000293:Adolescent; D000328:Adult; D000925:Anticoagulants / Q000009:adverse effects; D001021:Aortic Valve / Q000601:surgery; D002648:Child; D004696:Endocarditis / Q000209:etiology; D005260:Female; D006333:Heart Failure / Q000401:mortality; D006349:Heart Valve Diseases / Q000601:surgery; D006350:Heart Valve Prosthesis / Q000009:adverse effects / Q000401:mortality; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D008943:Mitral Valve / Q000601:surgery; D011247:Pregnancy; D011474:Prosthesis Design; D012086:Reoperation; D013529:Surgical Wound Dehiscence / Q000209:etiology; D015996:Survival Rate; D013923:Thromboembolism / Q000453:epidemiology / Q000209:etiology
D000925:Anticoagulants